

anti-Human Tremelimumab Monoclonal Antibody | anti-CTLA4 antibody

Research Grade Tremelimumab

CATALOG #
AAA120050

REACTIVITY
Human


PRODUCT SYNONYMS

Tremelimumab; Monoclonal Antibody; Research Grade Tremelimumab; Ticilimumab; CP-675; 206; CP-675206 clone 11.2.1; CD152; Cytotoxic T-lymphocyte protein 4; CTLA-4; CTLA4; Cytotoxic T-lymphocyte-associated antigen 4; anti-CTLA4 antibody

PRODUCT SPECIFICATIONS


Reactivity	Human
Clonality	Monoclonal
Isotype	IgG2-kappa
Clone Number	Tremelimumab
Purity/Purification	>95% as determined by SDS-PAGE; Protein A or G purified from cell culture supernatant.
Form/Format	Liquid. 0.01M PBS, pH 7.4
Concentration	1.21 mg/ml (varies by lot)
Host Species	Human
Preparation and Storage	Store at -20 degree C short term. Store at -80 degree C long term. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

IMAGES




Application Data

The purity of this product is >95% as determined by SEC-HPLC.



SDS-PAGE

SDS PAGE for Tremelimumab



Bioactivity

Detects Human CD152/CTLA4 in direct ELISAs.

ADDITIONAL INFORMATION

Product Categories/Family for anti-CTLA4 antibody	Research Biosimilar
References	Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial, PMID: 33285097 Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study, PMID: 32294530 Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial, PMID: 32971005 ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer, PMID: 32201234 Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial, PMID: 30383184

NCBI AND UNIPROT INFORMATION

NCBI GI #	27735177
NCBI GeneID	1493
UniProt Accession #	P16410; O95653; Q0PP65; Q52MC1; Q53TD5; Q5S005; Q8WXJ1; Q96P43; Q9UKN9; A0N1S0; E9PDH0
NCBI Official Full Name	Cytotoxic T-lymphocyte protein 4
NCBI Official Synonym Full Names	cytotoxic T-lymphocyte-associated protein 4
NCBI Official Symbol	CTLA4
NCBI Official Synonym Symbols	CD; GSE; GRD4; CD152; CTLA-4; IDDM12; CELIAC3
NCBI Protein Information	cytotoxic T-lymphocyte protein 4; CD152 isoform; celiac disease 3; cytotoxic T-lymphocyte antigen 4; insulin-dependent diabetes mellitus 12; cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated serine esterase-4; cytotoxic T lymph
UniProt Protein Name	Cytotoxic T-lymphocyte protein 4
UniProt Gene Name	CTLA4
UniProt Synonym Gene Names	CD152; CTLA-4
UniProt Entry Name	CTLA4_HUMAN

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

